Source-grounded facts extracted from Evofem Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Saundra Pelletier was appointed as Secretary at Evofem Biosciences, Inc..
“On April 5, 2023, the Company’s board of directors appointed Saundra Pelletier to fill the role as the Secretary of the Company, which was left vacant as a result of the resignation by Justin J. File.”
Justin J. File resigned as Secretary at Evofem Biosciences, Inc..
“which was left vacant as a result of the resignation by Justin J. File.”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $538,461.54 (effective 2023-03-20).
“On March 20, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $538,461.54 (the “ Notes ”) and warrants (“ Warrants ”) to purchase an aggregate 26,923,077 shares of common stock”
Evofem Biosciences, Inc. announced a restructuring with charges of aggregate pre-tax charges of approximately $0.1 million in connection with the reduction in force, primarily consisting of notice period and severance payments, affecting Company-wide (office and management positions) (39% reduction of payroll expenses; elimination of eight office and management positions including Chief Commercial Offic).
“On March 20, 2023 the Board of Directors of Evofem Biosciences, Inc. (the “Company”) approved a reduction in force (“RIF”) intended to conserve the Company’s current cash resources and manage operating expenses. The Company will reduce its current workforce resulting in an overall 39% reduction of payroll expenses including (i) salary cuts for certain employees, (ii) elimination of eight office and management positions including the elimination of the Chief Commercial Officer role effective March 17, 2023; and (iii) reduction of the Chief Executive Officer’s salary by 40%. The Company expects annualized future cost savings from the reduction in force to be approximately $4.3 million, which the Company intends to use to support its operations. The Company estimates that it will incur aggregate pre-tax charges of approximately $0.1 million in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs. The Comp”
Katherine Atkinson was terminated as Chief Commercial Officer at Evofem Biosciences, Inc..
“In connection with the RIF, the Company terminated the employment of Katherine Atkinson as the Company’s Chief Commercial Officer, effective March 17, 2023.”
Evofem Biosciences, Inc. shareholders approved Approval of an amendment to the Company's Certificate of Incorporation to effectuate a reverse stock split of the outstanding shares of the Company's common stock by a ratio of not less than 1-for-20 and not more than 1-for-125 at any time on or prior to March 15, 2024, with the exact ratio to be se at the 2023-03-15 meeting.
“Proposal No. 1: The Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to effectuate a reverse stock split of the outstanding shares of the Company’s common stock by a ratio of not less than 1-for-20 and not more than 1-for-125 at any time on or prior to March 15, 2024, with the exact ratio to be set at a whole number within such range by the Company’s board of directors (the “Board”), at the sole discretion of the Board, as follows: Votes For Votes Against Abstentions Broker Non-Votes 132,595,045 23,270,478 1,693,299 0”
Evofem Biosciences, Inc. faced acceleration on debt of approximately $92.8 million representing two times the sum of the outstanding balance and all accrued and unpaid interes with Baker Bros. Advisors, LP maturing within three business days of receipt of the Notice of Default.
“The Designated Agent, at the director of the Purchasers, has accelerated repayment of the outstanding balance payable and elected its remedies pursuant to Section 5.07(b) of the Securities Purchase Agreement. As a result, approximately $92.8 million representing two times the sum of the outstanding balance and all accrued and unpaid interest thereon and all other amounts due under the SPA and other documents is due and payable within three business days of receipt of the Notice of Default.”
Albert Altro was appointed as Chief Financial Officer at Evofem Biosciences, Inc..
“On March 6, 2023, Albert Altro was appointed as the interim Chief Financial Officer of the Company.”
Justin J. File resigned as Chief Financial Officer at Evofem Biosciences, Inc..
“On March 3, 2023, Justin J. File provided his notice of resignation from his role as Chief Financial Officer of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.”
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate original principal amount of $1,384,615.39 (effective 2023-02-17).
“On February 17, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company” ), entered into a securities purchase agreement (“ SPA” ), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,384,615.39 (the “ Notes” ) and warrants (“ Warrants” ) to purchase an aggregate 69,230,769 shares of common stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering” ). The Offering closed on February 17, 2023 (the “ Closing Date” ) and as a result, the Company issued an aggregate $1,384,615.39 in the aggregate principal amount of Notes and Warrants to purchase 69,230,769 shares of Common Stock.”
Jenny Yip resigned as Director at Evofem Biosciences, Inc..
“On February 10, 2023, Jenny Yip notified Evofem Biosciences, Inc., a Delaware corporation (the “Company”), of her resignation as member of the Company’s board of directors (the “Board”), effective immediately.”
Evofem Biosciences, Inc.: 公司提交指定证书创建D系列优先股，构成公司章程修订 (effective 2022-12-16).
“On December 16, 2022 the Company filed a certificate of designation to create the Series D Preferred Stock (the “ Certificate of Designation” ) with the Secretary of State, Division of Corporations in Delaware.”
Evofem Biosciences, Inc. entered into "SPA" with certain investors valued at $2,307,692 (effective 2022-12-20).
“On December 20, 2022, Evofem Biosciences, Inc., a Delaware corporation (the “ Company” ), entered into a securities purchase agreement (“ SPA” ), with certain investors (the “ Investors ”) providing for the sale and issuance of senior secured convertible notes due in the aggregate original principal amount of $2,307,692 (the “ Notes” ), warrants to purchase an aggregate 46,153,847 shares of common stock (“ Warrants” ) and an aggregate 70 shares of Series D Preferred Stock (the “ Preferred Shares ”) (collectively, the “ Offering” ).”
Justin J. File was appointed as Secretary at Evofem Biosciences, Inc..
“On December 19, 2022 Company appointed Justin J. File as Secretary, effective December 16, 2022.”
Evofem Biosciences, Inc. announced a restructuring with charges of The Company estimates that it will incur aggregate pre-tax charges of approximately $0.7 million in connection with the reduction in force, primarily consisting affecting workforce (45 employees).
“On November 1, 2022, the Board of Directors of Evofem Biosciences, Inc. (the "Company") approved a reduction in force intended to conserve the Company's current cash resources. The Company will reduce its current workforce by 45 employees. The Company expects annualized future cost savings from the reduction in force to be approximately $11.0 million, which the Company intends to use to support its operations. The Company estimates that it will incur aggregate pre-tax charges of approximately $0.7 million in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs. The Company expects that the reduction in force will be complete by the end of November 2022 and that these one-time charges will be incurred in the fourth quarter of 2022.”
Alexander A. Fitzpatrick resigned as General Counsel and Secretary at Evofem Biosciences, Inc..
“On October 10, 2022, Alexander A. Fitzpatrick, the General Counsel and Secretary of Evofem Biosciences, Inc. (the “Company”) tendered his resignation to the Company, effective October 14, 2022.”
Jenny Yip was elected as Director at Evofem Biosciences, Inc..
“On August 2, 2022, the Board of Directors (the “Board”) of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), elected Jenny Yip, to the Board to fill the existing vacancy on the Board.”
William Hall resigned as member of the Board at Evofem Biosciences, Inc..
“On November 17, 2021, William Hall, Ph.D., M.D. notified the Board of Directors (the "Board") of Evofem Biosciences, Inc., a Delaware corporation (the "Company"), of his intention to resign as a member of the Board effective immediately due to health concerns.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.